Ozempic Face: What It Is, Why It Happens, and What the Evidence Says

“Ozempic face” is a media term, not a diagnosis. It describes a face that looks thinner, hollower or saggier after losing a lot of weight on semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro). What we know points to the weight loss itself, not to the drug acting on your skin: when you lose weight, you lose fat from your face too, and with age, skin bounces back less. No US or EU label mentions loss of facial fat, and I haven’t found any trial that measures it.

Where the term comes from

The phrase took off with a New York Times article published January 24, 2023. It described people asking for facial fillers after losing weight on these drugs. It’s journalism: it reports what doctors were seeing, without measuring anything.

The evidence is still thin. A 2025 systematic review gathered 23 publications on these drugs and the face, almost all in plastic or aesthetic surgery journals. Only 3 were cohort studies with a comparison group. Of the rest, one was a survey of surgeons, one a systematic review, and the others letters, reviews, opinion pieces and case reports. The authors point out that there’s no proof these drugs reduce fat in the face more than anywhere else.

The same review notes that in the US, searches for “Ozempic face” rose at the same time as searches for “facial filler” and “plastic surgeon”. It adds that many companies already sell products aimed at these effects, which is worth keeping in mind as you read about the topic.

Why your face changes when you lose weight

Your face isn’t one solid block. A classic anatomy study by Rohrich and Pessa (2007) showed that the fat under facial skin sits in separate compartments: forehead, temples, around the eyes, cheeks, the fold between nose and mouth (the nasolabial fold) and the jawline. The authors link part of facial aging to how these compartments change over time.

When you lose a lot of weight, those compartments lose volume too. According to the 2025 review, losing fat in the temples, cheeks, under the eyes, along the jawline and in the folds around the mouth and nose can give a gaunt look that resembles accelerated aging.

Age shifts the balance:

• Skin has less collagen as the years go by. Collagen is the protein that keeps skin firm, and in a classic study it declined with age and was lower in women at every age. The 2025 review notes that facial changes after weight loss are more marked in older people, who have less collagen.
• Weight doesn’t “age” you the same way at every age. In 186 pairs of identical twins, a body mass index (BMI) 4 points higher was linked to looking older before age 40, but younger after 40. Past a certain age, some facial fat hides the years.

None of this is unique to GLP-1 medications. Some authors cited in the 2025 review argue that these drugs don’t target facial fat at all: they reveal age-related laxity that a thicker layer of fat used to hide.

Does the drug act directly on your skin?

According to the labels, there’s no sign of it. I went through the adverse reactions in the US prescribing information for Wegovy, Zepbound and Ozempic, and in the EU prescribing information for Wegovy, Mounjaro and Ozempic. None of them mentions loss of facial fat or skin aging. The face only comes up as a place where swelling can appear during a serious allergic reaction. Here’s what the US labels do report that relates to skin and hair:

Effect	Wegovy (semaglutide)	Zepbound (tirzepatide)	Ozempic (semaglutide)
Hair loss	3.3% vs. 1% on placebo with 2.4 mg; in the 7.2 mg trials, 5.8% vs. 3.3% with 2.4 mg and 1.0% on placebo	5%, 4% and 5% with 5, 10 and 15 mg, vs. 1% on placebo	Listed only among postmarketing reports (alopecia); frequency unknown
Altered skin sensation (dysesthesia: tingling, burning, sensitive or painful skin)	2% vs. 1% with 2.4 mg; in the 7.2 mg trials, 22% vs. 6% with 2.4 mg and 0.3% on placebo; 5% vs. none on placebo with the 25 mg tablets	0.2%, 0.2% and 0.4% with 5, 10 and 15 mg, vs. 0.1% on placebo	Listed only among postmarketing reports; frequency unknown

US labels checked on September 23, 2026 (Wegovy revised 6/2026, Zepbound revised 8/2026, Ozempic in its June 2026 DailyMed version). The 7.2 mg figures come from separate trials with their own 2.4 mg group. The Wegovy label adds that altered skin sensation became more frequent as the dose, and drug levels in the blood, went up.

The EU prescribing information pools the trials differently. For Wegovy, it reports hair loss in 2.5% vs. 1.0% on placebo with 2.4 mg, 5.3% vs. 1.0% with 7.2 mg, and 6.4% vs. 2.0% with the tablets. The US label doesn’t break out hair loss for the tablets; it says their common side effects were similar to the injection’s. For altered skin sensation, the EU figures are 2.1% vs. 1.2% with 2.4 mg and 21.6% vs. 0.3% with 7.2 mg. For tirzepatide, sold in the EU as Mounjaro for both diabetes and weight management, hair loss is “common” (between 1 and 10 in 100 people), mainly in people with overweight or obesity, and altered skin sensation is “uncommon” (between 1 and 10 in 1,000). The EU information for Ozempic doesn’t list hair loss, and lists changes in skin sensation with a frequency that can’t be estimated.

The Zepbound label also reports hypersensitivity (allergic) reactions in 5% of people at each dose vs. 3% on placebo in the weight-reduction trials, most of them skin reactions such as rash or itching. The EU prescribing information for Mounjaro gives 5.0% vs. 3.8% on placebo in the weight-management trials, sometimes severe (for example, hives, eczema, rash or dermatitis).

How much weight people lose in the trials, and how fast

Trial	Who	Length	Average weight loss
STEP 1, semaglutide 2.4 mg	1,961 adults without diabetes	68 weeks	14.9% (15.3 kg, about 34 lb), vs. 2.4% on placebo
SURMOUNT-1, tirzepatide 5, 10 and 15 mg	2,539 adults without diabetes, averaging 104.8 kg (231 lb) at the start	72 weeks	15.0%, 19.5% and 20.9%, vs. 3.1% on placebo

In STEP 1, half of the people on semaglutide (50.5%) lost at least 15% of their weight. In SURMOUNT-1, 57% of those on 15 mg lost at least 20%.

The average pace is slower than people tend to think. My own math: 15.3 kg over 68 weeks is about 0.2 kg (0.5 lb) a week; 20.9% of 104.8 kg over 72 weeks is about 0.3 kg (0.7 lb) a week. The UK’s National Health Service suggests 0.5 to 1 kg (1 to 2 lb) a week as a general goal. These are averages, and everyone moves at their own pace. The EU prescribing information for Wegovy adds that in the two-year STEP 5 trial, average weight went down until week 68 and then leveled off.

My reading: what sets these drugs apart is the total amount of weight lost more than the speed. According to the 2025 review, people usually lose at most about 25% of their weight with medication. That’s less than the massive losses after bariatric surgery, but some of the same volume and skin problems show up.

Hair loss: what the labels say, and what telogen effluvium is

The US labels for Wegovy and Zepbound both say hair loss was associated with weight reduction. Both report it more often in women: 4% of women and 0.9% of men on Wegovy 2.4 mg, and 7.1% of women vs. 0.5% of men on Zepbound, where no one stopped treatment because of it.

The EU prescribing information for Wegovy adds details the US label doesn’t give. With the injection, hair loss was mostly mild, more frequent in people who lost 20% of their weight or more, and most people recovered while staying on treatment. With the tablets, about half of the cases resolved before the trial ended.

All of this fits telogen effluvium: diffuse, temporary hair shedding. After a physical stress, such as losing a lot of weight, many hair follicles enter their resting phase at the same time, and the hair falls out weeks or months later. It isn’t unique to these drugs:

• In a 2024 Korean dermatology study of 140 people with telogen effluvium after weight loss, the average loss was 15.2% of body weight, at 3.5 kg (7.7 lb) a month. Everyone improved, on average within 4.8 months, without treatment. Women developed it while losing weight more slowly than men did, and older people with smaller losses. It’s a retrospective study, based on weights the patients recalled.
• After bariatric surgery, a 2025 meta-analysis of 41 studies with 7,044 patients estimates that 47% had hair loss.

The 2025 joint advisory from four US obesity and nutrition societies lists excessive hair shedding among the signs of possible nutrient deficiency, along with flaky skin and unusual tiredness. If you notice them, talk to your doctor.

What has support for looking after your face and body

A caveat: no study has measured whether any of these changes the face of someone on a GLP-1. They’re supported for other reasons.

• The pace of weight loss is up to your doctor. It depends on the drug, the dose and how it’s increased. The 2025 advisory notes that the pace of weight loss affects bone loss, and calls for adjusting nutrition to that pace. If you’re worried about your face, bring it up at your appointment: it’s useful information.
• Protein and strength training. This is the combination with the most support for keeping lean mass while you lose weight. I go through the numbers in protein and muscle on GLP-1 medications, and you can estimate your own target with the protein calculator (in Spanish; it works in kilograms, so divide pounds by 2.2). The big picture of eating on treatment is in what to eat on GLP-1 medications.
• Daily sunscreen. It has trial evidence against skin aging. In an Australian trial of 903 adults under 55, people who used sunscreen every day showed no detectable increase in skin aging after 4.5 years, and aged 24% less than those who used it at their own discretion.
• Drinking enough. The main reason is that nausea, vomiting and diarrhea can dehydrate you: the Wegovy and Zepbound Medication Guides warn that they may cause a loss of fluids (dehydration), which may cause kidney problems. As for skin, a systematic review found only 6 studies, all of weak quality. Drinking more may add a little moisture to the outer layer, mostly in people who drank little to begin with.
• Sleep. In an experiment with 23 adults, their faces were rated as less healthy and more tired after a short night followed by 31 hours awake. It’s a small study of extreme sleep loss, and the differences were modest.

What has little or no evidence

• Collagen supplements. A 2025 meta-analysis of 23 trials with 1,474 people found improvements in hydration, elasticity and wrinkles when all the trials were pooled. But in the trials without industry funding, and in the highest-quality ones, there was no effect. The authors conclude there’s no clinical evidence to support using them against skin aging. None of the trials looked at loss of facial volume.
• Creams. I haven’t found any trials of creams in people who lost facial volume after losing weight.

Fillers and other cosmetic procedures

There are treatments that restore volume or tighten skin, such as injectable fillers. They’re medical procedures with risks. The FDA warns of common side effects such as bruising, swelling or pain. It also warns of rare but serious risks if the product gets into a blood vessel: tissue death, vision problems including blindness, and stroke.

I don’t recommend specific clinics or treatments here. If you’re considering one, the FDA advises going to a licensed health care provider with experience in dermatology or plastic surgery. The 2025 review points out that before cosmetic surgery, surgeons look at several factors, including whether your weight has been stable.

The part the mirror doesn’t show

Watching your face change can be hard, even if you feel better on the inside, and that’s understandable. It helps to remember that “Ozempic face” is a media label, and that a thinner face isn’t a sick face.

The goal of obesity treatment is health, not a number on the scale or a particular face. If worry about how you look leads you to eat much less than you need, or to check yourself over and over, reach out for professional help: your doctor, a therapist or an eating-disorder specialist.

Frequently asked questions

Does your face go back to normal after stopping the drug?

No study has measured it. What we do know is that when treatment stops, much of the weight comes back. In the STEP 1 extension, people who had lost 17.3% of their weight regained about two-thirds of it within a year. In SURMOUNT-4, those switched to placebo gained 14.0% over 52 weeks. The 2025 review speculates that the gaunt look might soften as weight returns, but also notes that fat rarely redistributes the way it was before. I explain the regain side in what happens when you stop Ozempic, Wegovy or Zepbound. Whether to stop treatment is a decision to make with your doctor.

Does it only happen with Ozempic?

No. It comes with any substantial weight loss, whether from a drug, a diet or surgery.

Does it happen to everyone?

No. How much weight you lose and your age matter most. In the twin study, the effect of 4 extra BMI points on the face reversed after age 40.

Is the hair loss permanent?

Usually not: with Wegovy injections, most people recovered while staying on treatment (EU prescribing information), and in the Korean study everyone improved. If the shedding is heavy or lasts a long time, talk to your doctor.

Can collagen prevent it?

There’s no evidence it does: the 2025 meta-analysis found no effect in the highest-quality trials.

Which doctor can help?

For your treatment, the person who prescribes it. For skin and hair, a dermatologist. For volume-restoring procedures, a dermatologist or a plastic surgeon.